Abionyx Pharma (FRA:609) Short Interest


FRA:609 Abionyx Pharma FRA:609
15 GF Score
Price €2.17
GF Value €0.80
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Abionyx Pharma Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:609 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Abionyx Pharma's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abionyx Pharma Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abionyx Pharma's Short Interest distribution charts can be found below:

* The bar in red indicates where Abionyx Pharma's Short Interest falls into.


FRA:609
15GF Score
Abionyx Pharma FRA:609
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Abionyx Pharma (FRA:609) Overvalued in 2026?

Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued. The current stock price of €2.17 is trading 171.3% above its estimated GF Value™ of €0.80. GuruFocus considers Abionyx Pharma to be Significantly Overvalued.

Key valuation signals for FRA:609:

  • Short Interest:
  • GF Value™: €0.80 vs. price of €2.17 (171.3% above fair value)
  • GF Score™: 15/100 with 4 warning signs

No single metric tells the full story. See the FRA:609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abionyx Pharma Business Description

Address 33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
15GF Score

Get the complete analysis for FRA:609

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.17
Price
€0.80
GF Value